News
PHIO
0.6783
+1.09%
0.0073
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Nucor Corporation tumbled 6.5% to $179.20 on Tuesday. The company reported worse-than-expected quarterly financial results. Cyngn Inc. Shares jumped 100% after the company was chosen to supply John Deere with industrial automation. Pineapple Energy Inc. And Virgin Galactic Holdings, Inc. Were among the stocks moving in today's mid-day session.
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Calix, Fiserv, Quest Diagnostics
U.S. Stocks set to rise at open as some growth and chip stocks gain. Dow e-minis were up 0.28% in early trading. Spotify Technology, Fiserv, Quest Diagnostics among top percentage gainers. Investors digested a raft of quarterly earnings updates.
Reuters · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers ImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. Nuwellis shares increased by 24.1% and VolitionRX stock increased by 16.66% during the same time period. Losers Abeona Therapeutics and OncoCyte stock declined by 45.7% and 16.34% respectively.
Benzinga · 2d ago
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of Hibbett, Inc. Rose sharply in today's pre-market trading. The company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash. Pineapple Energy Inc. Shares gained 38% to $0.0632 after falling 10% on Monday. ImmunityBio, Inc., AGBA Group Holding Limited and HWH International were among the stocks moving in pre- market trading.
Benzinga · 2d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
HWH International (NASDAQ:HWH) stock is rocketing more than 64% alongside heavy pre-market trading. Pineapple Energy shares are soaring close to 40% on plans to regain listing compliance. The biggest pre- market stock movers on Tuesday morning are delisting updates, proposed public offerings, earnings reports and more.
Investorplace · 2d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. Sensei Biotherapeutics and Cognition Therapeutics among the gainers. Losers include Phio Pharma and Rigel Pharmaceuticals.
Benzinga · 3d ago
Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?
Phio Pharmaceuticals Corp is presenting new data about its lead clinical product candidate, PH-762. The shares are trading higher on a strong session volume of over 5 million. The company's lead product candidate is an INTASYL compound. The drug is being tested as a neoadjuvant therapy for cancer.
Benzinga · 3d ago
Phio's Intratumoral Injection Of PH-762 Significantly Inhibits Tumor Growth In Murine Tumor Models And May Generate Memory-Specific T Cells; Injection In Murine Tumors Shows The Compound Is Well Tolerated
-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma. Data will be presented at the American Society of Gene and Cell Therapy on May 8.
Benzinga · 3d ago
PHIO PHARMACEUTICALS CORP - INJECTION IN MURINE TUMORS SHOWS COMPOUND IS WELL TOLERATED
Reuters · 3d ago
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
Barchart · 3d ago
Weekly Report: what happened at PHIO last week (0415-0419)?
Weekly Report · 3d ago
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Phio Pharmaceuticals Corp. Is presenting new data about its lead clinical candidate, PH-762. The data will be presented in three posters at the annual meeting of the Society for Investigative Dermatology in Dallas, Texas. The company's proprietary INTASYL™ gene silencing technology is designed to make immune cells more effective in killing tumor cells.
Barchart · 04/16 06:30
Weekly Report: what happened at PHIO last week (0408-0412)?
Weekly Report · 04/15 10:09
PHIO PHARMACEUTICALS ANNOUNCES UPCOMING PRESENTATION AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CELL AND GENE THERAPY (ASCGT)
Reuters · 04/11 11:30
Weekly Report: what happened at PHIO last week (0401-0405)?
Weekly Report · 04/08 10:12
National Spotlight Features Phio’s Innovative RNAi Technology Platform
Program will be airing on PBS with Dennis Quaid in April. INTASYL platform will be the focus of Viewpoint. The program will air in April on PBS stations across the country. It will also be seen on Fox Business Network. Phio Pharmaceuticals Corp. Is a clinical stage biotechnology company.
Barchart · 04/03 06:30
Phio Pharmaceuticals on the Brink: Nasdaq Delisting Looms Over Falling Stock Prices
TipRanks · 04/03 06:01
PHIO Stock Earnings: Phio Pharma Beats EPS for Q4 2023
Phio Pharma reported earnings per share of -17 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. Phio Pharma's results were above the analyst estimate for EPS of -$1.30. The company just reported results for fourth quarter.
Investorplace · 04/02 15:52
Phio Pharmaceuticals GAAP EPS of -$5.20
Phio Pharmaceuticals Corp. Reports FY GAAP EPS of -$5.20. At December 31, 2023 we had cash of $8.5 million as compared to $11.8 million at the end of 2022. The company is expected to report quarterly earnings of $0.02 per share.
Seeking Alpha · 04/02 11:39
*Phio Pharmaceuticals 2023 Loss/Shr $5.20 >PHIO
Dow Jones · 04/02 11:36
More
Webull provides a variety of real-time PHIO stock news. You can receive the latest news about Phio Pharmaceuticals Corp through multiple platforms. This information may help you make smarter investment decisions.
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.